News | May 08, 2025
Sigachi Industries receives CEP for Metformin Hydrochloride from EDQM
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
The company's first-ever corporate-level submission to EcoVadis builds on years of operational and environmental excellence
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma
Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
The Q1 2025 also witnessed a successful launch of Allegra D
Niacin is indicated to reduce elevated total cholesterol, LDL cholesterol, apolipoprotein B and triglycerides (TG)
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
Priced at just Rs. 499 for 1-year supply, this initiative is aligned with the vision of Health for All
This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Subscribe To Our Newsletter & Stay Updated
